Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers.
This study included 15 patients with gynaecological cancers (7 with cervical cancer, 6 with endometrial cancer, and 12 with ovarian cancer); 7 with benign gynaecological disorders (5 with benign ovarian tumour and 2 with uterine myoma); and 10 healthy women as a control group. Serum interleukin-1 receptor antagonist (IL-1 ra) levels in patients with gynaecological cancer were significantly higher than those in patients with benign gynaecological disorders (P = 0.04) and in healthy controls (P = 0.0009). IL-1 ra may play an important role in host immune responses in local and general environments against gynaecological cancers.
Fujiwaki
R
R
Department of Obstetrics and Gynaecology, Chiyoda Central Hospital, Japan.
Hata
T
T
Miyazaki
K
K
Kawamura
T
T
Inada
K
K
D016889:Endometrial Neoplasms / Q000097:blood / Q000378:metabolism*; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000097:blood; D010051:Ovarian Neoplasms / Q000097:blood / Q000378:metabolism*; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000378:metabolism*
D007375:Interleukin-1; D017472:Receptors, Interleukin-1